A Nature Communications study mapped how genetic variation in complement system genes impacts pancreatic cancer risk and prognosis (5824da7fa241d818). The analysis integrated genomic datasets to link complement gene polymorphisms to tumor microenvironment features and survival differences. Lead takeaway: specific complement gene variants associate with altered immune infiltration and clinical outcomes in pancreatic ductal adenocarcinoma; authors propose complement genetics as both a susceptibility factor and a potential prognostic biomarker. The study uses large patient cohorts and multiomic correlation. For precision oncology groups, the findings prompt consideration of complement pathway biomarkers in patient stratification and suggest complementary therapeutic strategies targeting innate immunity in pancreatic cancer.